Natus Medical Inc (NASDAQ:BABY) Director Ken Ludlum sold 30,000 shares of the business’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $31.02, for a total transaction of $930,600.00. Following the completion of the transaction, the director now directly owns 73,957 shares in the company, valued at $2,294,146.14. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of NASDAQ:BABY opened at $34.11 on Thursday. The company has a current ratio of 2.62, a quick ratio of 1.89 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $1.15 billion, a P/E ratio of 24.19 and a beta of 0.52. Natus Medical Inc has a fifty-two week low of $27.69 and a fifty-two week high of $41.55.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, October 24th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.42 by ($0.02). The company had revenue of $130.60 million during the quarter, compared to analysts’ expectations of $132.92 million. Natus Medical had a positive return on equity of 11.34% and a negative net margin of 3.53%. Natus Medical’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same period last year, the firm posted $0.40 earnings per share. On average, analysts expect that Natus Medical Inc will post 1.48 EPS for the current year.

A number of brokerages recently weighed in on BABY. BidaskClub downgraded shares of Natus Medical from a “buy” rating to a “hold” rating in a report on Friday, September 7th. Zacks Investment Research raised shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, August 10th. ValuEngine raised shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, November 16th. Finally, Roth Capital set a $36.00 price target on shares of Natus Medical and gave the stock a “buy” rating in a report on Thursday, October 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $42.50.

Several large investors have recently modified their holdings of BABY. Factorial Partners LLC purchased a new stake in Natus Medical during the third quarter valued at about $111,000. Sei Investments Co. lifted its holdings in Natus Medical by 46.3% during the second quarter. Sei Investments Co. now owns 4,669 shares of the medical equipment provider’s stock valued at $161,000 after purchasing an additional 1,478 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Natus Medical by 1,010.8% during the second quarter. Tower Research Capital LLC TRC now owns 5,132 shares of the medical equipment provider’s stock valued at $177,000 after purchasing an additional 4,670 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new stake in Natus Medical during the second quarter valued at about $201,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Natus Medical during the third quarter valued at about $204,000. 94.40% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/insider-selling-natus-medical-inc-baby-director-sells-930600-00-in-stock/2663931.html.

About Natus Medical

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

See Also: What is a balanced fund?

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.